Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics

New York, USA, July 16, 2024 (GLOBE NEWSWIRE) -- Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx

GlobeNewswire13:00 ET

Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says

Biogen (BIIB) needs to acquire additional revenue-generating assets for the turnaround to complete, Wedbush said in a Tuesday note to clients.The company has indicated capacity for $8 billion to $10

MT NewswiresJul 16 11:27 ET

Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen

Seeking AlphaJul 16 11:10 ET

Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification

TipRanksJul 16 07:05 ET

Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating

Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ.Price: 222.01, Change: +0.43, Percent Change: +0.19

MT NewswiresJul 16 06:24 ET

Jeito Capital Consolidates Its Support in CatalYm With a Renewed Participation in a $150 Million Financing

Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing

GlobeNewswireJul 16 05:10 ET